Archives

  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br M Mizuno Y Shiomi K I Minato

    2020-08-12


    [14] M. Mizuno, Y. Shiomi, K.I. Minato, S. Kawakami, H. Ashida, H. Tsuchida, Fucogalactan isolated from Sarcodon aspratus elicits release of tumor necrosis factor-α and nitric oxide from murine macrophages, Immunopharmacology 46 (2000) 113–121.
    [22] E. Brauchle, S. Thude, S.Y. Brucker, K. Schenke-Layland, Cell death stages in single apoptotic and necrotic cells monitored by Raman microspectroscopy, Sci. Rep. -UK (2014) 4.
    [24] V. Mohacek-Grosev, R. Bozac, G.J. Puppels, Vibrational spectroscopic character-ization of wild growing mushrooms and toadstools, Spectrochim. Acta A Mol. Spectrochim. Acta A 57 (2001) 2815–2829.
    [40] R. Goldman, E. Ferber, R. Meller, U. Zor, A role for reactive oxygen species in zymosan and beta-glucan induced protein tyrosine phosphorylation and phospho-lipase A2 activation in murine macrophages, Biochim. Biophys. Acta 1222 (1994) 265–276.
    [56] M.K. Lu, T.Y. Lin, C.H. Chao, C.H. Hu, H.Y. Hsu, Molecular mechanism of Antrodia cinnamomea sulfated polysaccharide on the suppression of lung cancer cell growth and migration via induction of transforming growth factor beta receptor degrada-tion, Int. J. Biol. Macromol. 95 (2017) 1144–1152.
    Contents lists available at ScienceDirect
    Lung Cancer
    journal homepage: www.elsevier.com/locate/lungcan
    Anti-tumoral activity of the human-specific duplicated form of α7-nicotinic T receptor subunit in tobacco-induced lung cancer progression
    José Luis Cedilloa,1, Anna Bordasa,1, Francisco Arnalichb, , Isabel Esteban-Rodríguezc, Carolina Martín-Sáncheza, María Extremeraa, Gema Atienzaa, Juan J. Riosb, Raquel L. Arribasa, Carmen Montiela,
    a Department of Pharmacology and Therapeutics, School of Medicine, Universidad Autónoma de Madrid-IdiPAZ, Madrid, Spain
    b Internal Medicine Service, University Hospital La Paz of Madrid-IdiPAZ, Madrid, Spain
    c Pathology Service, University Hospital La Paz of Madrid-IdiPAZ, Madrid, Spain
    Keywords: α7 Nicotinic VX-765 receptor dupα7 Nicotinic receptor subunit Non-small cell lung cancer
    Tobacco smoke
    Nicotine
    Nitrosamines 
    Objectives: Tobacco smoking is strongly correlated with the onset and progression of non-small cell lung cancer (NSCLC). By activating α7 nicotinic acetylcholine receptors (α7-nAChRs) in these tumors nicotine and its to-bacco-derived nitrosamine, NNK, contribute to these oncogenic processes. Here, we investigated whether the human-specific duplicated form of the α7-nAChR subunit (dupα7) behaves as an endogenous negative regulator of α7-nAChR-mediated tumorigenic activity induced by tobacco in NSCLC cells, similarly to its influence on other α7-nAChR-controlled functions in non-tumor cells.
    Methods: Two human NSCLC cell lines, lung adenocarcinoma (A549) and squamous cell carcinoma of the lung (SK-MES-1), both wild-type or with stable overexpression of dupα7 (A549dupα7 or SK-MES-1dupα7), were used to investigate in vitro anti-tumor activity of dupα7 on nicotine- or NNK-induced tumor progression. For this purpose, migration, proliferation or epithelial-mesenchymal transition (EMT) were examined. The anti-tumor effect of dupα7 on nicotine-promoted tumor growth, proliferation or angiogenesis was also assessed in vivo in an athymic mouse model implanted with A549dupα7 or A549 xenografts. Results: Overexpression of dupα7 in both cell lines almost completely suppresses the in vitro tumor-promoting effects induced by nicotine (1 μM) or NNK (100 nM) in wild-type cells. Furthermore, in mice receiving nicotine, A549dupα7 xenografts show: (i) a significant reduction of tumor growth, and (ii) decreased expression of cell markers for proliferation (Ki67) or angiogenesis (VEGF) compared to A549 xenografts.
    Conclusion: Our study demonstrates, for the first time, the in vitro and in vivo anti-tumor capacity of dupα7 to block the α7-nAChR-mediated tumorigenic effects of tobacco in NSCLC, suggesting that up-regulation of dupα7 expression in these tumors could offer a potential new therapeutic target in smoking-related cancers.
    1. Introduction
    Lung cancer is the leading global cause of cancer deaths, with non-small cell lung cancer (NSCLC) accounting for 75–85% of all lung cancer cases [1]. Lung adenocarcinoma and squamous cell carcinoma of
    the lung are the two major histological types of NSCLC. Cigarette smoking is an important risk factor for many types of cancers, including NSCLC, which is understandable because tobacco smoke contains more than 70 known carcinogens that will eventually initiate carcinogenesis [2,3]. In parallel with the mutagenic and cytotoxic effects of these
    Abbreviations: α7-nAChR, α7 nicotinic acetylcholine receptor subtype; dupα7, human-specific duplicated form of the α7-nAChR subunit; EMT, epithelial-me-senchymal transition; ERK, extracellular signal-regulated kinase; FBS, fetal bovine serum; HRP, horseradish peroxidase; IHC, immunohistochemistry; MEK, mitogen-activated protein kinase; NNK, nicotine-derived nitrosamine 4-(methylnitrosamino)-1-(3-pyrydyl)-1-butanone; NSCLC, non-small cell lung cancer; p90RSK, MAPK-activated protein kinase-1; PVDF, polyvinylidene difluoride; qPCR, real-time quantitative PCR; Raf-1, RAF proto-oncogene serine/threonine-protein kinase; Rb, retinoblastoma tumor suppressor protein; SCLC, small cell lung cancer; VEGF, vascular endothelial grown factor